Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia

Platelets

Volumn 8, Issue 1, 1997, Pages 74-81

  Magnani, H N ^a  

^a MRDU   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; DANAPAROID; HEPARIN;

CONFERENCE PAPER; DEEP VEIN THROMBOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0030888763     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Meuleman D. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65.
2. Bradbrook I, Magnani HN, Moelker HC, Morrison PJ, Robinson J, Rogers HJ, Spector RG, Van Dinther T, Wijand H. Org 10172 a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987; 23: 667-75.
3. Danhof M, de Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172). Haemostasis 1992; 22: 73-84.
4. Adams HP, Woolson RF, Biller J, Clarke W. Studies of Ortg 10172 in patients with acute ischaemic stroke. Haemostasis 1992; 22: 99-103.
5. Ten Cate JW. Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Haemostasis 1992; 22: 109-11.
6. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meurrisen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK. Comparing subcutaneous Danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. Ann Intern Med 1995; 123: 1-9.
7. Henny CP, Ten Cate H, Ten Cate JW, Surachno S, van Bronswijk H, Wilmink JM, Ockelford PA. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; i: 890-3.